Literature DB >> 20139026

Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.

Jane M Fall-Dickson1, Sandra A Mitchell2, Susan Marden3, Edward S Ramsay4, Jean-Pierre Guadagnini5, Tianxia Wu6, Lena St John7, Steven Z Pavletic8.   

Abstract

Oral chronic graft-versus-host disease (cGVHD) is a frequent, clinically significant sequela of allogeneic hematopoietic stem cell transplantation (HSCT). This study was designed to elucidate relationships among clinical characteristics of oral cGVHD and related oral pain and oral dryness, salivary proinflammatory cytokine interleukin (IL)-6 and IL-1alpha concentrations, and health-related quality of life (HRQL). An understanding of the characteristics and correlates of oral cGVHD manifestations and related symptoms, such as oral dryness, is fundamental to the development of therapeutic interventions. Oral cGVHD severity was assessed with the Oral Mucositis Rating Scale (OMRS). Oral pain and perceived intensity of oral dryness were self-reported via a visual analog scale and a numeric rating scale, respectively. HRQL was assessed with the Functional Assessment of Cancer Therapy-General (FACT-G). Salivary IL-1alpha and IL-6 concentrations were measured by enzyme-linked immunosorbent assay. All 42 adult subjects (59% males) had clinician-assessed oral cGVHD by the OMRS scale (mean score, 18.38 +/- 12.99; range, 2-46). Oral dryness (in 43% of subjects; mean OMRS score, 2.56 +/- 3.45; range, 0-10) was more prevalent than oral pain (8%; mean score, 0.13 +/- 0.47). Salivary IL-6 was associated with oral cGVHD severity (r = 0.49; P < .01), oral ulceration (r = 0.38; P = .04), and erythema (r = 0.63; P < .01). FACT-G total score and physical and emotional well-being subscale scores were meaningfully lower than U.S. population normative values. Participants with more severe oral cGVHD manifestations had significantly inferior social/family well being (r = -0.49; P < .01). Oral dryness was associated with higher salivary IL-1alpha (r = 0.41; P = .04) and, controlling for cGVHD severity, with lower HRQL (r = -0.41; P = .03). Subjects with moderate to severe oral dryness tended to report the poorest overall HRQL. This study provides preliminary evidence of the relationship between oral dryness and HRQL, the contribution of oral cGVHD to inferior HRQL, and the association between IL-6 and oral cGVHD severity, ulceration, and erythema. The high prevalence of oral dryness and its relationship to HRQL in a sample of subjects with oral cGVHD underscores the importance of improving our evaluation and management of this symptom in long-term survivors of allogeneic HSCT. The positive associations between IL-6 and oral cGVHD severity and erythema, as well as the positive trend with oral ulceration, warrant further exploration of this cytokine as a potential biomarker of active oral cGVHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20139026      PMCID: PMC5443667          DOI: 10.1016/j.bbmt.2010.01.017

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  50 in total

1.  Oral and serum IL-6 levels in oral lichen planus patients.

Authors:  Gao Man Gu; Michael D Martin; Richard P Darveau; Edmond Truelove; Joel Epstein
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-12

Review 2.  Transplantation's greatest challenges: advances in chronic graft-versus-host disease.

Authors:  Warren D Shlomchik; Stephanie J Lee; Daniel Couriel; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

Review 3.  Cytokines in acute and chronic inflammation.

Authors:  C A Feghali; T M Wright
Journal:  Front Biosci       Date:  1997-01-01

4.  Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease.

Authors:  Kevin She; Andrew L Gilman; Soudabeh Aslanian; Hiromi Shimizu; Mark Krailo; Zhengjia Chen; Gregor S Reid; Donna Wall; Fred Goldman; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2007-02-15       Impact factor: 5.742

5.  Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF.

Authors:  Peter Szodoray; Philip Alex; Malin V Jonsson; Nicholas Knowlton; Igor Dozmorov; Britt Nakken; Nicolas Delaleu; Roland Jonsson; Michael Centola
Journal:  Clin Immunol       Date:  2005-08-26       Impact factor: 3.969

6.  Measurement of pain: the psychometric properties of the Pain-O-Meter, a simple, inexpensive pain assessment tool that could change health care practices.

Authors:  F Gaston-Johansson
Journal:  J Pain Symptom Manage       Date:  1996-09       Impact factor: 3.612

7.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

Authors:  Hisaki Fujii; Geoff Cuvelier; Kevin She; Soudabeh Aslanian; Hiromi Shimizu; Amina Kariminia; Mark Krailo; Zhengjia Chen; Rob McMaster; Axel Bergman; Frederick Goldman; Stephen A Grupp; Donna A Wall; Andrew L Gilman; Kirk R Schultz
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

8.  Association of Foxp3 regulatory gene expression with graft-versus-host disease.

Authors:  Yuji Miura; Christopher J Thoburn; Emilie C Bright; Michele L Phelps; Tahiro Shin; Elizabeth C Matsui; William H Matsui; Sally Arai; Ephraim J Fuchs; Georgia B Vogelsang; Richard J Jones; Allan D Hess
Journal:  Blood       Date:  2004-06-01       Impact factor: 22.113

9.  High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Nazmim S Bhuiya; Corey S Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

Review 10.  The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs.

Authors:  Richard M Logan; Andrea M Stringer; Joanne M Bowen; Ann S-J Yeoh; Rachel J Gibson; Stephen T Sonis; Dorothy M K Keefe
Journal:  Cancer Treat Rev       Date:  2007-05-15       Impact factor: 12.111

View more
  17 in total

1.  Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures.

Authors:  C W Bassim; H Fassil; J W Mays; D Edwards; K Baird; S M Steinberg; K M Williams; E W Cowen; S A Mitchell; K Cole; T Taylor; D Avila; D Zhang; D Pulanic; L Grkovic; D Fowler; R E Gress; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2013-09-02       Impact factor: 5.483

2.  Assessing the relationship between oral chronic graft-versus-host disease and global measures of quality of life.

Authors:  Joseph DePalo; Xiaoyu Chai; Stephanie J Lee; Corey S Cutler; Nathaniel Treister
Journal:  Oral Oncol       Date:  2015-08-12       Impact factor: 5.337

Review 3.  Oral Complications of Chronic Graft-Versus-Host Disease.

Authors:  Jane M Fall-Dickson; Steven Z Pavletic; Jacqueline W Mays; Mark M Schubert
Journal:  J Natl Cancer Inst Monogr       Date:  2019-08-01

4.  Malnutrition in patients with chronic GVHD.

Authors:  C W Bassim; H Fassil; M Dobbin; S M Steinberg; K Baird; K Cole; G Joe; L E Comis; S A Mitchell; L Grkovic; D Edwards; J W Mays; E W Cowen; D Pulanic; K M Williams; R E Gress; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2014-07-14       Impact factor: 5.483

5.  Quality of life trajectories during the first year following hematopoietic cell transplantation: an inception cohort study.

Authors:  Gerald M Devins; Kenneth Mah; Hans A Messner; Anargyros Xenocostas; Lise Gauvin; Jeffrey H Lipton
Journal:  Support Care Cancer       Date:  2018-02-08       Impact factor: 3.603

6.  Oral disease profiles in chronic graft versus host disease.

Authors:  C W Bassim; H Fassil; J W Mays; D Edwards; K Baird; S M Steinberg; E W Cowen; H Naik; M Datiles; P Stratton; R E Gress; S Z Pavletic
Journal:  J Dent Res       Date:  2015-03-04       Impact factor: 6.116

7.  Oral cGVHD screening tests in the diagnosis of systemic chronic graft-versus-host disease.

Authors:  Renata Gonçalves Resende; Jeane de Fátima Correia-Silva; Telma Cristina Arão; João Artur Ricieri Brito; Henrique Bittencourt; Ricardo Santiago Gomez; Mauro Henrique Nogueira Guimarães Abreu
Journal:  Clin Oral Investig       Date:  2011-03-03       Impact factor: 3.573

8.  Oral chronic graft-vs.-host disease characterization using the NIH scale.

Authors:  H Fassil; C W Bassim; J Mays; D Edwards; K Baird; S M Steinberg; K M Williams; E W Cowen; S A Mitchell; F T Hakim; T Taylor; D Avila; D Zhang; L Grkovic; M Datiles; R E Gress; S Z Pavletic
Journal:  J Dent Res       Date:  2012-07       Impact factor: 6.116

Review 9.  Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research.

Authors:  J W Mays; H Fassil; D A Edwards; S Z Pavletic; C W Bassim
Journal:  Oral Dis       Date:  2012-10-28       Impact factor: 3.511

10.  Proteomic analysis of saliva from patients with oral chronic graft-versus-host disease.

Authors:  Ivana Devic; Min Shi; Mark M Schubert; Michele Lloid; Kenneth T Izutsu; Catherine Pan; Melody Missaghi; Thomas H Morton; Lloyd A Mancl; Jing Zhang; Richard B Presland
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.